An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Completed · Phase 2

Conditions studied: Atypical Hemolytic-Uremic Syndrome

In brief

The primary purpose is to assess the efficacy and safety of eculizumab in pediatric patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment.

Key facts

Study ID

NCT01193348

Run by

Alexion Pharmaceuticals, Inc.

People needed

22

Starts

2010-09-01

Expected to finish

2014-04-01

Last updated by the study team

2015-04-29

Who can join

Age: 0 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Atlanta, Georgia, United States
• Study site — Hackensack, New Jersey, United States
• Study site — Corpus Christi, Texas, United States
• Study site — Spokane, Washington, United States
• Study site — North Adelaide, South Australia, Australia
• Study site — Ghent, Belgium
• Study site — Toronto, Ontario, Canada
• Study site — Lille, France
• Study site — Marseille, France
• Study site — Paris, France
• Study site — Rouen, France
• Study site — Hanover, Germany
• Study site — Milan, Italy
• Study site — Palermo, Italy
• Study site — Nijmegen, Netherlands
• Study site — London, United Kingdom
• Study site — Nottingham, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.